HCV has complex interactions with human lipid metabolism leading to downregulation of cholesterol levels. Treatment with DAAs was proven to induce a sharp and significant increase in total and low-density lipoprotein cholesterol (LDL) persisting after the end of treatment (EOT). It has been suggested that the increased risk of cardiovascular disease (CVD) associated with ritonavir-boosted darunavir (DRV/r) use may be independent from dyslipidaemia [1]. The aim of this analysis was to examine cholesterol changes in HIV-HCV coinfected patients after HCV clearance and according to DRV/r, ATV/r or RAL exposure during DAA.
Increased total and LDL cholesterol plasma levels upon direct antiviral agents (DAAs) driven HCV eradication.
G. Nunnari;G. F. Pellicanò
2018-01-01
Abstract
HCV has complex interactions with human lipid metabolism leading to downregulation of cholesterol levels. Treatment with DAAs was proven to induce a sharp and significant increase in total and low-density lipoprotein cholesterol (LDL) persisting after the end of treatment (EOT). It has been suggested that the increased risk of cardiovascular disease (CVD) associated with ritonavir-boosted darunavir (DRV/r) use may be independent from dyslipidaemia [1]. The aim of this analysis was to examine cholesterol changes in HIV-HCV coinfected patients after HCV clearance and according to DRV/r, ATV/r or RAL exposure during DAA.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.